ArticleAmerican journal of translational research2025
The impact of combination chemotherapy administration on prognostic outcomes in stage II and III gastric cancer: a comprehensive analysis utilizing propensity score matching.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLimited data are available on the effects of combined and intravenous or oral chemotherapy on the survival of patients who have undergone D2 gastrectomy for cancer.
methodsThis study involved 1314 patients who participated in a trial that followed D2 gastrectomy with adjuvant or neoadjuvant chemotherapy.
resultsFollowing propensity score matching (PSM), the results indicated that contrary to expectations, combined chemotherapy administration was associated with poorer overall survival (OS) and progression-free survival (PFS) at the 5-year mark for stage II gastric cancer, with log-rank
conclusionsThe findings suggest that the concurrent use of oral and intravenous chemotherapy after D2 gastrectomy does not enhance the prognosis for gastric cancer patients compared to using either modality alone. Instead, it appears to increase the risk of disease progression for stage III patients and the likelihood of recurrence for both stages II and III of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.